Get in touch.
Stay connected.


message.png

Whether you have product-related questions or need Repatha® samples, Repatha® Sales Representatives are here to help you and your office staff.

First Name

Enter first name

Last Name

Enter last name

Email

Enter email address

Zip Code

Enter zip code

I am a...

Select your title

Phone Number

Enter Phone Number

To report an adverse event, please call 1-800-77-AMGEN (1-800-772-6436).

Privacy Statement
By clicking "Submit," you agree to disclose your personal information to Amgen and to be contacted by Amgen and their agents in the future regarding products, services, and/or information related to Repatha®. For more information about Amgen's privacy practices, please visit www.amgen.com/privacy.


Submit

Thank you.


Submit

MECHANISM OF ACTION

Repatha® helps the liver clear LDL cholesterol by limiting the actions of a protein called PCSK9—and less PCSK9 means less LDL-C in the blood.1

Statins reduce production of cholesterol

Via inhibition of HMG-CoA reductase, statins reduce the production of plasma cholesterol and lipoprotein.2


Repatha® enhances removal of LDL-cholesterol

By inhibiting PCSK9, Repatha® increases the number of LDL-C receptors on the surface of the liver, resulting in reduction of LDL-C from circulation.1



Repatha® mechanism of action1

What is PCSK9?

PCSK9 is a protein that promotes degradation of low density lipoprotein receptors (LDLRs). This results in fewer LDLRs on the liver cell surface, increasing plasma LDL-C levels.

Watch video

5:45

Why Repatha® inhibits PCSK9

By inhibiting the binding of PCSK9 to LDLR, Repatha® permits LDLRs to recycle back to the liver cell surface. This, in turn, increases the number of LDLRs available to clear LDL-C from the blood, thereby lowering LDL-C levels.

Watch video

0:23

How Repatha® lowers LDL-C levels

Repatha® lowers LDL-C levels by inhibiting PCSK9, increasing the number of LDLRs on the hepatocyte surface, thereby resulting in lower LDL-C plasma concentrations.

Watch video

0:18


References: 1. Repatha® (evolocumab) prescribing information, Amgen. 2. Lipitor® (atorvastatin) prescribing information, Pfizer Inc.

Important Safety Information

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Allergic Reactions: Hypersensitivity reactions (e.g. angioedema, rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse Reactions in Primary Hyperlipidemia (including HeFH): The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52‐week trial and seven 12‐week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®‐treated and placebo‐treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising.

Allergic reactions occurred in 5.1% and 4.7% of Repatha®‐treated and placebo‐treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new‐onset diabetes mellitus during the trial was 8.1% in patients assigned to Repatha® compared with 7.7% in those assigned to placebo.

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please see full Prescribing Information.

What is PCSK9?

X

Why Repatha® inhibits PCSK9

X

How Repatha® lowers LDL-C levels

X